On February 25, 2020, the Securities and Exchange Commission ("SEC") announced that Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a biopharmaceutical company based in Madison, Wis., has agreed to pay $75 million to settle a pending litigation action brought by the SEC.  The SEC's complaint alleges that Aclaris violated the antifungal antifungal antifungal antibody registration provisions of the federal securities laws.  According to the complaint, Aclaris failed to comply with the antifungal antifungal registration provisions of the federal securities laws.  The SEC's complaint, filed in federal court in Madison, Wis., alleges that Aclaris failed to comply with the registration provisions of the federal securities laws.  In a parallel action, the U.S. Attorney's Office for the Southern District of New York today announced criminal charges against Aclaris.  The SEC's complaint charges Aclaris with violating the antifungal antifungal provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Aclaris has agreed to settle the SEC's charges without admitting or denying the allegations in the complaint.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, has been conducted by Sarah Ruffo, Melissa Gordon, and Lisa Blair, and the litigation will be led by Ms. Gordon.  The SEC appreciates the assistance of the U.S. Attorney's Office, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.